HC Wainwright Boosts Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright upped their Q3 2025 EPS estimates for shares of Kodiak Sciences in a research note issued on Tuesday, November 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.04) per share for the quarter, up from their prior estimate of ($1.05). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($4.10) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.76) EPS.

KOD has been the subject of several other reports. Jefferies Financial Group assumed coverage on Kodiak Sciences in a research note on Monday, September 22nd. They set a “buy” rating and a $15.00 price objective for the company. Lifesci Capital initiated coverage on Kodiak Sciences in a research report on Thursday, October 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Wall Street Zen downgraded Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, October 11th. Chardan Capital reaffirmed a “neutral” rating and set a $14.00 price objective on shares of Kodiak Sciences in a research note on Monday, October 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $22.33.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $19.51 on Thursday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.74 and a beta of 2.88. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $21.17. The firm’s 50 day moving average price is $15.15 and its two-hundred day moving average price is $8.96.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.09).

Institutional Trading of Kodiak Sciences

A number of hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. purchased a new position in Kodiak Sciences during the first quarter valued at approximately $236,000. GSA Capital Partners LLP boosted its stake in shares of Kodiak Sciences by 163.6% during the 1st quarter. GSA Capital Partners LLP now owns 205,833 shares of the company’s stock valued at $577,000 after buying an additional 127,748 shares during the period. XTX Topco Ltd purchased a new position in shares of Kodiak Sciences during the 1st quarter valued at $126,000. US Bancorp DE increased its stake in shares of Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after acquiring an additional 5,276 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Kodiak Sciences by 8.9% during the first quarter. Deutsche Bank AG now owns 73,564 shares of the company’s stock worth $207,000 after acquiring an additional 6,018 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.